Neuropharmacology and Neurotoxicity of 3,4-Methylenedioxymethamphetamine - Drugs of Abuse: Neurological Reviews and Protocols - page 66

33. Lew, R., Sabol, K. E., Chou, C., Vosmer, G. L., Richards, J., and Seiden, L. S.
(1996) Methylenedioxymethamphetamine-induced serotonin defi cits are followed
by partial recovery over a 52-week period. Part II: Radioligand binding and
autoradiography studies. J. Pharmacol. Exp. Ther. 276, 855-865.
34. Fischer, C., Hatzidimitriou, G., Wios, J., Katz, J., and Ricaurte, G. (1995)
Reorganization of ascending 5-HT axon projections in animals previously exposed
to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA,
“Ecstasy”). J. Neurosci. 15, 5476-5485.
35. Commins, D. L., Vosmer, G., Virius, R., Woolverton, W. L., Schuster, C. R., and
Seiden, L. S. (1987) Biochemical and histological evidence that methylenedioxy-
methamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol.
Exp. Ther. 241, 338-344.
36. Scallet, A. C., Lipe, G. W., Ali, S. F., Holson, R. R., Frith, C. H., and Slikker, W., Jr.
(1988) Neuropathological evaluation by combined immunohistochemistry and
degeneration-specifi c methods: application of methylenedioxymethamphetamine.
Neurotoxicology 9, 529-538.
37. O'Callaghan, J. P. and Miller, D. B. (1993) Quantifi cation of reactive gliosis as an
approach to neurotoxicity, in Assessing Neurotoxicity of Drugs of Abuse (Erinoff,
L., ed.), NIDA Monograph 136, pp. 188-212.
38. Callahan, B. T., Cord, B. J., and Ricaurte, G. A. (2001) Long-term impairment of
anterograde axonal transport along fi ber projections originating in the rostral raphe
nuclei after treatment with fenfl uramine or methylenedioxymethamphetamine.
Synapse 40, 113-121.
39. Gudelsky, G. A., Wallace, T. L., Vorhees, C. V., and Zemlan, F. P. (2001) Metham-
phetamine enhances the cleavage of the cytoskeletal protein tau in the striatum
and hippocampus of the rat. Soc. Neurosci. Abstr. 358.6.
40. Schmidt, C. J., Black, C. K., Abbate, G. M., and Taylor, V. L. (1990) Antagonism of
the neurotoxicity due to a single administration of methylenedioxymethamphet-
amine. Eur. J. Pharmaocol. 181, 59-70.
41. Aguirre, N., Barrionuevo, M., Lasheras, B., and Del Río, J. (1998) The role
of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxy-
methamphetamine-induced neurotoxicity in rats. J. Pharmacol. Exp. Ther. 286,
1159-1165.
42. Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1988) Role of endog-
enous dopamine in the central serotonergic defi cits induced by 3,4-methylene-
dioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79-87.
43. Shankaran, M., Yamamoto, B. K., and Gudelsky, G. (1999) Mazindol attenuates the
3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and
long-term depletion of serotonin in the striatum. J. Neurochem. 72, 2516-2522.
44. Kanthasamy, A. and Nichols, D. E. (2002) Unilateral injection of dopamine
transporter antisense oligonucleotide into the substantia nigra protects against
MDMA-induced serotonergic defi cits in the ipsilateral striatum. Soc. Neurosci.
Abstr., No. 445.18.